OAC
ANVS icon

OMERS Administration Corp’s Annovis Bio ANVS Stock Holding History

OMERS Administration Corp’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,100
Closed -$215K – 1101
2025
Q4 		$215K Buy
+62,100
New +$187K ﹤0.01% 898

Other funds holding ANVS

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

OMERS Administration Corp's ANVS Position: Q1 2026 in Review

OMERS Administration Corp sold out of Annovis Bio (ANVS) in Q1 2026, closing a stake of 62,100 shares — an estimated $215K sold.

OMERS Administration Corp first reported a position in ANVS in Q4 2025 and held it in 1 quarter. The position peaked at $215K in Q4 2025. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • OMERS Administration Corp reported no remaining Annovis Bio position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 62,100 Annovis Bio shares in Q1 2026, an estimated $215K.
  • OMERS Administration Corp first reported a position in Annovis Bio in Q4 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Annovis Bio position peaked at $215K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.